HKMPF OTC
Credit Risk of going bust: lower than 62% of companies Debt: 29.9% of company value Bonds: none of note held by US funds details ▾
Total debt $1.95B against a stock market value of $4.58B.
Distance to default 6.51 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.04B (short-term plus half of long-term), stock volatility 31.6%; Altman Z'' 4.48. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
London, GL W1H 6AZ
GB
Hikma Pharmaceuticals PLC is a global pharmaceutical firm engaged in the development, manufacturing, commercialization, and distribution of a wide array of medications, including its own branded products, licensed drugs, and generic formulations. These pharmaceutical offerings come in various forms, such as solids, semi-solids, liquids, and injectables. The company's operations are divided into three core segments: Injectables, which primarily supplies generic injectable medications to hospitals; Generics, focusing on oral and other non-injectable generic drugs for the retail market; and Branded, which provides both proprietary generics and in-licensed pharmaceuticals to retail consumers and healthcare institutions. Hikma's product portfolio addresses a broad spectrum of medical needs, spanning anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory disorders. Founded in 1978 and based in London, United Kingdom, the company extends its reach across the UK, the United States, the Middle East, North Africa, Europe, and other international markets.
